T1	Participants 47 159	patients with metastatic renal cell carcinoma previously treated with a tyrosine kinase inhibitor and everolimus
T2	Participants 175 226	36 patients treated in France in the RECORD-1 Trial
T3	Participants 286 377	patients with metastatic renal cell carcinoma (mRCC) typically receive multiple treatments.
T4	Participants 378 503	Guidelines recommend everolimus for patients previously treated with tyrosine kinase inhibitors (TKI) sunitinib or sorafenib.
T5	Participants 561 626	patients with disease progression after a TKI-everolimus sequence
T6	Participants 921 972	Thirty-six patients received a TKI after everolimus
